Skip to main content
All lobbying filings

ARENTFOX SCHIFF LLP

Lobbying for PHARVARIS, INC. · Late-stage biopharmaceutical company

 Filing Registration
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 15, 2025
Money reported
None
Registrations and no-activity reports carry no figure.
Client based in
Massachusetts

Official filing document

 Lobbyists on this filing 6
  • KELSEY GRISWOLD-BERGER New on this filing
    Previously held: Leg Asst, Sen. Burr (2021-2023); Leg Dir, Rep. C. Smith (2018-2021); Leg Dir, Rep. Pittenger (2018); Leg Dir, Rep. Blum (2017-2018); Leg Asst, Rep. Perry (2015-2017); Leg Asst (2014-2015), Leg Corr/Press Asst (2011-2014), Staff Asst (2011), Rep. Reed
  • OLIVER SPURGEON III New on this filing
    Previously held: Legislative Correspondent, Rep. Hank Johnson (2009-2015); Staff Assistant, Rep. Hank Johnson (2007-2009)
  • PHILIP ENGLISH Former member of Congress New on this filing
    Previously held: U.S. Representative (1995-2009)
  • STARSHINE CHUN New on this filing
    Previously held: Executive Assistant/Deputy Scheduler, Sen. Brian Schatz (2021-2023)
  • DANIEL SJOSTEDT New on this filing
    Previously held: Staff Assistant, Rep. Jeff Fortenberry (2016-2017)
  • LAURA EUGSTER DOYLE New on this filing
    Previously held: Legislative Director, Rep. Philip English (1998-2002)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

 Lobbying activity 4
Health Issues

Advocacy of policies, legislation and regulation pertaining to pharmaceutical manufacturing, focusing on orphan drug production

Medicare/Medicaid

Advocacy of policies, legislation and regulation pertaining to pharmaceutical manufacturing, focusing on orphan drug production

Pharmacy

Advocacy of policies, legislation and regulation pertaining to pharmaceutical manufacturing, focusing on orphan drug production

Trade (domestic/foreign)

Advocacy of policies, legislation and regulation pertaining to pharmaceutical manufacturing, focusing on orphan drug production

 Foreign interests disclosed 2

Section 7 of the LD-2: foreign entities that own part of the client, paid toward this lobbying, or stand to benefit from it.

  • PHARVARIS GMBH
    Switzerland · Zug · owns 100% of the client · contributed $0.00
  • PHARVARIS N.V.
    Netherlands · Leiden · owns 100% of the client · contributed $0.00

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem